Healthcare Industry News: Tryton Medical
News Release - September 24, 2007
OmniSonics Appoints J. Daniel Cole Chairman of the BoardWILMINGTON, Mass., Sept. 24 (HSMN NewsFeed) -- OmniSonics Medical Technologies, Inc., a leading developer of advanced medical devices for occlusive vascular disease, today announced the appointment of J. Daniel Cole as the company's new Chairman of the Board.
Mr. Cole is a founding partner with Spray Venture Partners, a venture capital firm that focuses exclusively on emerging healthcare technology companies. He brings twenty years of medical device operational experience, having served on the boards of 10 companies, two of which he started. Prior to joining Spray, Mr. Cole served as senior vice president and group president of Boston Scientific Corporation's (BSC) vascular business, a $1.2 billion group, and was also responsible for BSC's international operations. Prior to BSC, he was president and chief iperating officer of SCIMED Life Systems before the company's merger with Boston Scientific. He also held a variety of executive and general management positions at Baxter Healthcare. He currently serves on the Board of Directors of Acorn Cardiovascular, Tryton Medical, Direct Flow Medical, and Tremont Medical, and is actively involved in Kolis Scientific, PneumRx, and Thoratec Laboratories.
"We are thrilled to have Dan Cole as our new Chairman of the Board for OmniSonics," said Richard Ganz, president and CEO, OmniSonics Medical Technologies. "Over the last few years, we have been actively building a world-class team with in-depth experience in product development and commercialization. Dan's experience and leadership will be a major asset as we launch our products for vascular occlusive disease and build a word-class commercial enterprise."
"This is an exciting time to join the OmniSonics team," said J. Daniel Cole, Chairman of the Board and partner at Spray Venture Partners. "The company has assembled a management team with over 80 cumulative years of experience in medical devices and commercial operations. They have developed breakthrough technology for treating vascular occlusive disease - technology that has the chance to have a major impact on a serious health issue. The company is ready for the transition from R&D to commercialization, and I'm looking forward to being a part of that transition."
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease. The Company plans to introduce products based on its patented OmniWave(TM) Technology, the first technology capable of delivering low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave Technology is designed to have broad applications in vascular occlusive conditions. Clearance for use in peripheral vascular disease is expected in 2007. Additional clinical trials are planned for other indications.
Source: OmniSonics Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.